Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

ASCELIA Aktie

>ASCELIA Performance
1 Woche: -10,2%
1 Monat: -16,2%
3 Monate: -18,1%
6 Monate: -17,7%
1 Jahr: -5,3%
laufendes Jahr: -18,1%
>ASCELIA Aktie
Name:  ASCELIA PHARMA AB
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0010573113 / A2H81X
Symbol/ Ticker:  7ZA (Frankfurt)
Kürzel:  FRA:7ZA, ETR:7ZA, 7ZA:GR
Index:  -
Webseite:  https://www.ascelia.com/
Profil:  Ascelia Pharma AB (publ) is a biotech company specializing in the development and commercialization of novel drugs for orphan oncology treatments. The company focuses on addressing unmet medical needs in rare cancer conditions through two key drug ca..
>Volltext..
Marktkapitalisierung:  32.68 Mio. EUR
Unternehmenswert:  28.19 Mio. EUR
Umsatz:  -
EBITDA:  -
Nettogewinn:  -7.15 Mio. EUR
Gewinn je Aktie:  -0.06 EUR
Schulden:  0.09 Mio. EUR
Liquide Mittel:  4.67 Mio. EUR
Operativer Cashflow:  -6.77 Mio. EUR
Bargeldquote:  4.02
Umsatzwachstum:  -
Gewinnwachstum:  4.72%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  ASCELIA
Letzte Datenerhebung:  05.04.26
>ASCELIA Kennzahlen
Aktien/ Unternehmen:
Aktien: 126.87 Mio. St.
Frei handelbar: 96.23%
Leerverk. Aktien: -
Rückkaufquote: -19.8%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: No rating
Kursziel: 193.1%
Bewertung:
KGV: -
KGV lG: 11.31
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -60.31%
Eigenkaprendite: -85.48%
>ASCELIA Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung, Nierenerkrankungen & -behandlung
 
30.03.26 - 16:54
 Notice of Annual General Meeting in Ascelia Pharma AB (Accesswire)
 
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / March......
27.03.26 - 14:42
 Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026 (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / March 27, 2026 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with ......
05.02.26 - 08:06
 Ascelia Pharma: Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / February 5, 2026 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today published its Full Year and Q4 Report for 2025 (January - December), which is now available on ......
21.01.26 - 11:06
 Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / January 21, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today announced that Deputy CEO Julie Waras Brogren will leave the company to take up a CEO position in another c......
21.01.26 - 10:54
 Ascelia-Aktie fällt um 4 % nach Abgang der Finanzchefin (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
22.12.25 - 07:54
 Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / December 22, 2025 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today announces that the Nomination Committee for the Annual General Meeting (AGM) on 4 May 2026 has......
28.11.25 - 15:30
 Change in Number of Shares and Votes in Ascelia Pharma AB (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / November 28, 2025 / Ascelia Pharma (STO:ACE)During the month of November, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total......
19.11.25 - 15:30
 Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / November 19, 2025 / Ascelia Pharma (STO:ACE) - The Board of Directors of Ascelia Pharma AB ("Ascelia Pharma") has on 19 November 2025 resolved to convert 53,335 series......
15.11.25 - 12:30
 Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / November 15, 2025 / Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that ......
10.11.25 - 09:42
 Ascelia Pharma Files New Patent Application for Orviglance (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / November 10, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditi......
05.11.25 - 08:06
 Ascelia Pharma: Quarterly Report Q3 2025: Orviglance NDA Submitted to the FDA (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / November 5, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE) today published its Interim Report Q3 for 2025 (January - September), which is now ......
03.11.25 - 11:30
 Ascelia Pharma Announces Management Changes to Support Future Growth (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / November 3, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditio......
30.09.25 - 07:54
 Change in Number of Shares and Votes in Ascelia Pharma AB (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / September 30, 2025 / During September, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma")(STO:ACE) has increased due to conversion of ou......
03.09.25 - 10:42
 Ascelia Pharma Submits Orviglance New Drug Application to the U.S. Food and Drug Administration (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / September 3, 2025 / Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that t......
02.09.25 - 16:27
 Ascelia Pharma: Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / September 2, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB ("Ascelia Pharma" or the "Company") issued on 13 September 2024, convertibles to Fenja Capital II A/S ......
21.08.25 - 08:06
 Ascelia Pharma: Half-Year Report 2025: Orviglance NDA Submission Approaching (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / August 21, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker: ACE) today published its Half-Year Report for 2025 (January - June), which is now availa......
15.08.25 - 18:54
 Ascelia Pharma Updates Timeline for Submission of the Orviglance NDA (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / August 15, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer condition......
16.05.25 - 07:54
 Ascelia Pharma: Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / May 16, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q1 for 2025 (January - March), which is now availab......
07.05.25 - 16:54
 Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025 (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / May 7, 2025 / Ascelia Pharma (STO:ACE) - Today, on 7 May 2025, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows be......
30.04.25 - 12:06
 Change in Number of Shares and Votes in Ascelia Pharma AB (Accesswire)
 
MALMÖ, SE / ACCESS Newswire / April 30, 2025 / Ascelia Pharma (STO:ACE)During April, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the exerc......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!